Elisabetta Ricottini

Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of MYocardial Damage during Angioplasty–Contrast-Induced Nephropathy] Trial

Giuseppe Patti, Elisabetta Ricottini, Annunziata Nusca et al. · The American Journal of Cardiology · 2011 · 187 citations

Percutaneous Coronary Intervention, Contrast-induced Nephropathy, Cardiovascular Disease +12

Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study)

Giuseppe Patti, Vincenzo Pasceri, Vincenzo Vizzi et al. · The American Journal of Cardiology · 2011 · 114 citations

Percutaneous Coronary Intervention, Thrombosis, Point-of-care Testing +13

A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention

Fabio Mangiacapra, Giuseppe Patti, Emanuele Barbato et al. · JACC: Cardiovascular Interventions · 2012 · 90 citations

Thrombopoiesis, Thrombosis, Percutaneous Coronary Intervention +13

Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation

Giuseppe Patti, Markus Lucerna, Ilaria Cavallari et al. · Journal of the American College of Cardiology · 2017 · 83 citations · Full text

Thrombosis, Diabetes Management, Cardiovascular Disease +13

Comparison of Platelet Reactivity and Periprocedural Outcomes in Patients With Versus Without Diabetes Mellitus and Treated With Clopidogrel and Percutaneous Coronary Intervention

Fabio Mangiacapra, Giuseppe Patti, Aaron Peace et al. · The American Journal of Cardiology · 2010 · 81 citations

Thrombopoiesis, Thrombosis, Percutaneous Coronary Intervention +12